Kodiak Sciences Inc. reported a net loss of $57.5 million for the first quarter of 2025, an increase from $43.0 million in the same period last year. The company's cash and cash equivalents stood at $138.9 million, expected to support operations into 2026. R&D expenses rose due to increased clinical and manufacturing activities, while G&A expenses slightly decreased.

Kodiak Sciences reported a net loss of $44.1 million for Q4 2024, an improvement from $59.5 million in Q4 2023. The company's cash and cash equivalents stood at $168.1 million, which is expected to support operations into 2026. Research and development expenses decreased significantly, driven by reduced manufacturing activities and equity award forfeitures.

Kodiak Sciences reported a net loss of $43.9 million for the third quarter of 2024, with cash and cash equivalents of $197.9 million. The company is focused on advancing its clinical programs, including tarcocimab, KSI-501, and KSI-101, and expects current cash to support operations into 2026.

Kodiak Sciences reported a net loss of $45.1 million for the second quarter of 2024, with cash and cash equivalents of $219.2 million at the end of the quarter. The company is focusing on advancing its clinical programs for tarcocimab, KSI-501, and KSI-101, and has strengthened its executive team.

Kodiak Sciences reported a net loss of $43.0 million for the first quarter of 2024, with $245.9 million in cash and cash equivalents, which is expected to support operations into 2026. The company is advancing its clinical programs for tarcocimab, KSI-501, and KSI-101, with key milestones including the initiation of the DAYBREAK study and Phase 1b enrollment for the APEX study.

Kodiak Sciences reported a net loss of $59.5 million for the fourth quarter of 2023 and ended the year with $285.5 million in cash and cash equivalents. The company is progressing its three clinical assets towards Phase 3 value inflection points, including new Phase 3 studies for tarcocimab and KSI-501.

Kodiak Sciences reported a net loss of $50.0 million for the third quarter of 2023. The company ended the quarter with $345.7 million in cash and cash equivalents. The company is focusing on its pipeline of retinal disease prospects and plans to reboot the tarcocimab program.

Kodiak Sciences Inc. reported its second quarter 2023 financial results, highlighting a net loss of $80.2 million, progress with the KSI-501 clinical program, and the decision to wind down ongoing tarcocimab studies due to unfavorable Phase 3 GLEAM and GLIMMER study results.

Kodiak Sciences reported a net loss of $70.8 million for the first quarter of 2023, with cash, cash equivalents, and marketable securities totaling $421.2 million.

Kodiak Sciences reported a net loss of $70.4 million for the fourth quarter of 2022, with R&D expenses at $56.0 million and G&A expenses at $18.1 million. The company ended the quarter with $478.9 million in cash, cash equivalents, and marketable securities.

Kodiak Sciences reported a net loss of $77.0 million for the third quarter of 2022 and ended the quarter with $537.4 million in cash, cash equivalents and marketable securities. The company is focused on advancing its Phase 3 clinical program for tarcocimab tedromer.

Kodiak Sciences reported positive topline results from its Phase 3 pivotal study of tarcocimab tedromer in treatment-naïve patients with macular edema due to retinal vein occlusion. The net loss for the second quarter of 2022 was $90.6 million, or $1.74 per share.

Kodiak Sciences reported a net loss of $95.7 million for the first quarter of 2022 and ended the quarter with $671.7 million in cash and cash equivalents. The company is progressing with its KSI-301 Phase 3 program and anticipates four Phase 3 study readouts in 2022 and 2023.

Kodiak Sciences reported a net loss of $93.2 million for the fourth quarter of 2021, compared to a net loss of $46.6 million for the fourth quarter of 2020. The company ended the quarter with $731.5 million in cash and cash equivalents. The study did not meet its primary efficacy endpoint.

Kodiak Sciences reported a net loss of $67.5 million for the third quarter of 2021, with cash and cash equivalents of $799.2 million. The company is progressing with its KSI-301 clinical program and anticipates topline data readouts beginning in early 2022.

Kodiak Sciences reported a net loss of $55.9 million for the second quarter of 2021, with $880.9 million in cash and cash equivalents. The company is advancing its KSI-301 clinical program, including enrollment in Phase 3 studies for wet AMD, RVO, and DME.

Kodiak Sciences reported a net loss of $50.4 million for the first quarter of 2021, with R&D expenses increasing to $40.3 million due to higher clinical trial costs for KSI-301. The company ended the quarter with $929.0 million in cash, cash equivalents, and marketable securities.

Kodiak Sciences reported a net loss of $46.6 million for the fourth quarter of 2020, compared to a net loss of $15.6 million for the same period in 2019. The company ended the year with $969.0 million in cash, cash equivalents, and marketable securities. The increase in net loss and R&D expenses was primarily driven by higher clinical trial costs and increased manufacturing activities.

Kodiak Sciences reported its Q3 2020 financial results, highlighted by the continued progress of its KSI-301 pivotal study programs in wet AMD, DME, and RVO. The company ended the quarter with a strong cash position of $380.5 million, expected to fund operations into 2022.

Kodiak Sciences reported a net loss of $26.0 million for the second quarter of 2020. The company ended the quarter with $417.1 million in cash, cash equivalents and marketable securities, estimating sufficient funds to execute on current operating plans into 2022.

Kodiak Sciences reported its Q1 2020 financial results, highlighting a net loss of $24.4 million, or $0.54 per share. The company ended the quarter with $430.4 million in cash, cash equivalents, and marketable securities. Despite minimal disruption from COVID-19 in ongoing clinical trials, the initiation of the next set of KSI-301 pivotal studies was delayed by one quarter.

Kodiak Sciences reported a net loss of $15.6 million for the fourth quarter of 2019, with R&D expenses increasing to $12.8 million. The company ended the year with a strong cash position of $348.2 million, anticipating sufficient funds for operations for at least the next twelve months. Progress was marked by the advancement of KSI-301 through clinical trials and the establishment of key partnerships.